Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

8

Deferred tax assets, net 167,368 176,619

Other current assets 108,106 43,267

Total current assets 1,588,163 1,422,025

PROPERTY AND EQUIPMENT, net 501,575 500,396

GOODWILL 471,127 476,515

INTANGIBLE ASSETS, net 753,286 817,828

DEFERRED TAX ASSETS, net 171,865 141,752

OTHER ASSETS 169,589 147,753

$3,655,605 $3,506,269

CURRENT LIABILITIES:

Current portion of long-term debt $1,023,104 $1,237,169

Accounts payable 81,323 91,437

Accrued expenses 723,728 677,184

Total current liabilities 1,828,155 2,005,790

LONG-TERM DEBT 2,729 3,788

DEFERRED TAX LIABILITIES, net 72,088 56,540

OTHER LIABILITIES 180,539 138,084

Total liabilities 2,083,511 2,204,202

STOCKHOLDERS' EQUITY:

Common stock, $0.01 par value 713 700

Additional paid-in capital 2,050,035 1,934,965

Treasury stock, at cost (194,782) (158,173)

Accumulated deficit (413,166) (624,128)

Accumulated other comprehensive

income 129,294 148,703

Total stockholders' equity 1,572,094 1,302,067

$3,655,605 $3,506,269
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Chicago, Illinois (PRWEB) October 30, 2014 ... Regenerative and Cellular Medicine Showcase in Chicago, leading ... and Orthopedic Surgeon, Dr. Wade McKenna presented talks ... Effectiveness and Orthopedic Surgical Applications For Stem Cells. ... of amniotic membrane and the properties of AlphaGEMS ...
(Date:10/30/2014)... 30, 2014 Whitehouse Laboratories has formally ... Stability Testing and Package Test Capacity. Responding to growing ... a dramatic increase in environmental chamber storage space that ... and aging samples to be securely held on site ... capital expenditure has already taken place with the recent ...
(Date:10/30/2014)... BASKING RIDGE, N.J. , Oct. 30, 2014 /PRNewswire/ ... announced that it will hold a conference call and ... 8:30 a.m. EST to discuss its third quarter 2014 ... access the conference call by dialing (888) 347-1165 for ... conference call will be webcast live under the investor ...
(Date:10/27/2014)... 27, 2014 The Italian ... exhibit and sell its artificial "lower limb", after ... patent.      (Photo: http://photos.prnewswire.com/prnh/20141027/713097 ... fighting, the definitive judgement has arrived: Roadrunnerfoot, the ... and accessible hi-tech prostheses with composite materials, has ...
Breaking Biology Technology:Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Regado Biosciences to Provide Third Quarter 2014 Financial Results 2Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2
... Spherix Incorporated (NASDAQ: SPEX ) – ... syndrome and atherosclerosis, and provider of technical and regulatory ... today announced that it has entered into definitive agreements ... stock and warrants to purchase shares of its common ...
... +49(0)69-2222-34066 France: +33(0)1-70-48-01-63 U.K.: +44(0)20-7660-0009 ... is 5634610; to view the webcast, log onto: ... March 13, 2012 - Annual press conference in Goettingen, Germany ... Germany April 24, 2012 - Publication of first-quarter ...
... A relatively fast, easy and inexpensive technique for ... self-assemble into one-, two- and even three-dimensional macroscopic ... researchers with the U.S. Department of Energy (DOE),s ... should enable more effective use of nanorods in ...
Cached Biology Technology:Spherix Announces Registered Direct Offering of $1.15 Million 2Spherix Announces Registered Direct Offering of $1.15 Million 3Preliminary Figures for 2011: Sartorius Grows at Double-Digit Rates and Boosts Operating Earnings by More Than 30% 2Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks 2Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks 3Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks 4
(Date:10/31/2014)... In the war against Ebola one important hurdle has ... Researchers at the University of North Carolina at Chapel ... of mice that can be infected with Ebola and ... work, published in the current issue of Science ... and vaccines, which are desperately needed to curb the ...
(Date:10/31/2014)...  HITLAB SM , a healthcare innovation and ... HITLAB Innovators Summit SM on December 1, ... partner with the Clinton Foundation,s Health Matters Initiative, ... Business School Alumni Club of New ... Operations Research, bringing together leaders in healthcare and ...
(Date:10/30/2014)... in German . ... fellow humans to behave socially? This is one of ... theory. Previous studies assumed that it is almost impossible ... the Max Planck Institute for Evolutionary Biology have now ... on the cooperative behaviour of others. However, the possibilities ...
Breaking Biology News(10 mins):Improved mouse model will accelerate research on potential Ebola vaccines, treatments 2HITLAB Announces Inaugural HITLAB Innovators Summit 2HITLAB Announces Inaugural HITLAB Innovators Summit 3Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4
... This press release is available in German . ... pathogens and rogue cells in the body and put them out ... migrate from there into the thymus. Here, they mature and differentiate ... Institute of Immunobiology and Epigenetics in Freiburg have now succeeded for ...
... Deepwater Horizon oil spill in the Gulf of Mexico in April ... fisheries. A new study published in the Canadian Journal of ... 7 years this oil spill could have a $US8.7 billion impact ... in revenue, profit, and wages, and close to 22 000 jobs ...
... The understanding of diseases such as Parkinson,s and Alzheimer,s ... technology at which will enable cell analysis using automated ... School of Information Communication Technology and the Eskitis Institute ... the automated identification, separation and analysis of cells as ...
Cached Biology News:Live from the thymus: T-cells on the move 2Live from the thymus: T-cells on the move 3
... DNA Polymerase I Large (Klenow) Fragment, Exonuclease ... lacks both the 5´→3´ and the 3´→5´ ... DNA Polymerase I (1,2). It is used ... strand displacement amplification (5). Klenow Fragment, Exonuclease ...
SMVT (N-14)...
...
... Rabbit polyclonal to Dideoxycytidine Dideoxycytidine is a ... effective in inhibiting retroviral activity. Immunogen: ... Specificity: The specificity of the ... of the moles of ddC to moles of ...
Biology Products: